P149 Validation of the COPD assessment test (CAT) within α-1 antitrypsin deficiency (A1ATD). (16th November 2010)

• Record Type: Journal Article
• Authors: Edgar, R G; Griffiths, D; Stockley, R A
• Is Part Of: Thorax. Volume 65(2010)Supplement 4
• Page Start: A141
• Page End: A141
• Publication Date: 2010-11-16
• Subjects: Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thx.2010.150987.50
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Introduction and objectives: The COPD Assessment Test (CAT) has recently been validated with a USA cohort as a health status questionnaire (HSQ) for use in chronic obstructive pulmonary disease (COPD).1 Its purpose is to guide and improve communication between the health care professional and patient and identify key areas for health improvement. Historically, other HSQ have been used in COPD especially the St Georges Respiratory Questionnaire (SGRQ) which has been extensively validated for use in clinical care and trials. However the SGRQ has a complex scoring algorithm and requires several minutes to complete restricting its use in daily clinical practice.1 2 The CAT was developed as a user friendly, time efficient, easily analysed and reliable HSQ for COPD. We have an extensive database for patients with α-1 Antitrypsin Deficiency (A1ATD) and have an annual review at which the SGRQ is used. We wished to compare CAT with the SGRQ in these patients. Methods: 163 consecutive patients with A1ATD attending the Antitrypsin Deficiency Assessment and Programme for Treatment (ADAPT) centre were asked to complete both SGRQ and CAT prior to full Lung function and medical review. All patients were clinically stable (at least 6 weeks post exacerbation). SGRQ and CAT scores were compared as well as routine post bronchodilator lung function parameters to determine the relationships. Results: 157 patients completed both questionnaires. CAT correlated strongly with SGRQ total score (R 2 =0.799, p<0.0001, n=157) (Abstract P149 Figure 1 ) and its domains (impact R 2 =0.751, symptoms R 2 =0.59 and activity R 2 =0.66). CAT values also correlated with lung function including FEV1 %predicted (R 2 =0.26, p<0.0001, n=157), FEV1 /FVC (R 2 =0.224, p<0.0001, n=157), KCO %predicted (R 2 =0.151, p<0.0001, n=147) all of which were comparable to those seen with SGRQ. Conclusion: CAT offers a short HSQ that is simple to use and analyse, correlates well with the more complex SGRQ and stable lung function.